Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BNB Plus ( (BNBX) ) has provided an update.
On February 2, 2026, BNB Plus Corp. filled a board vacancy created by the resignation of a prior director by appointing digital asset veteran James Haft as an independent director and member of its Nominating Committee, a move announced publicly on February 5, 2026. Haft’s compensation package includes a $40,000 cash fee and stock options for 93,000 shares vesting over four dates through February 2, 2027, along with eligibility for future equity grants and coverage under the company’s standard indemnification agreement. With more than 35 years of experience across blockchain infrastructure, emerging markets and traditional finance, and a track record that includes founding digital-asset-focused merchant banking and blockchain education platforms, Haft is expected to bolster BNB Plus’s governance and strategic expertise as it scales its BNB treasury operations and DeFi yield capabilities, while the company has disclosed that his only related-party connection is an arm’s-length investment in an October 2025 PIPE by a fund co-founded by his son in which Haft has no management role.
Spark’s Take on BNBX Stock
According to Spark, TipRanks’ AI Analyst, BNBX is a Neutral.
Applied DNA Sciences faces substantial financial and operational challenges, as indicated by declining revenues and net losses. Despite some positive strategic moves, such as focusing on LineaRx, the stock suffers from poor technical indicators and valuation metrics. The company’s ongoing financial struggles and the uncertainties highlighted in the earnings call contribute to a low overall stock score.
To see Spark’s full report on BNBX stock, click here.
More about BNB Plus
BNB Plus Corp. (Nasdaq: BNBX), formerly Applied DNA Sciences, operates in the digital asset and biotechnology sectors, unlocking streamlined access to the Binance ecosystem through non-directional DeFi yield strategies and long BNB exposure supported by an actively managed BNB treasury. In parallel, the company continues to commercialize proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets, targeting investors traditionally excluded from high-performance digital assets while maintaining a legacy footprint in life sciences.
Average Trading Volume: 123,245
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.5M
Find detailed analytics on BNBX stock on TipRanks’ Stock Analysis page.